Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
PatSnap Eureka Desktop
NEWAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisOpen Platform
NEWProfessional Services
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report SHP2 inhibition combined with MEK, ERK, and KRAS G12C inhibitors is redefining treatment strategy for KRAS-driven PDAC, NSCLC, and colorectal cancer. Full pipeline analysis.
Article | Report Explore the 2026 magnetic microneedle technology landscape: patent trends, key assignees, magnetic actuation clusters, and strategic IP white spaces across 80+ records.
Article | Report A 2026 technology landscape of quantum dot infrared photodetectors (QDIPs): material systems, patent clusters, geographic activity, and emerging directions for R&D and IP strategy.
Article | Report How EUV photon shot noise, acid diffusion blur, and polymer microstructure drive LER at 3nm gate pitch — and the materials, process, and etch strategies that reduce transistor variability.
Article | Report SHP2 inhibition combined with KRAS G12C, MEK, and ERK inhibitors is reshaping treatment strategies for PDAC, NSCLC, and colorectal cancer. Explore the evidence.
Article | Report How photoresist LER drives transistor variability at 3nm gate pitch — root causes, device impact, and proven mitigation strategies from 20+ patents and papers.
Article | Report Explore the 2026 QDIP technology landscape: material systems, patent clusters, geographic trends, and emerging directions in infrared photodetector innovation.
Article | Report How substrate noise coupling degrades RF performance in bulk CMOS versus SOI technology for 5G transceivers — mechanisms, data, and patented mitigation strategies.
Article | Report How STING agonists, RIG-I activators, ENPP1 inhibitors, and advanced delivery platforms are reprogramming the tumor microenvironment in solid tumors.
Article | Report Enzymes, engineered microbes, and hybrid electro-biological systems are rewriting the carbon capture playbook. Explore the 2026 biocatalytic CO₂ technology landscape.
Article | Report How substrate noise coupling degrades RF performance in bulk CMOS versus SOI technology for 5G transceivers—mechanisms, circuit impacts, and patented mitigation strategies.
Article | Report Enzymes, engineered microbes, and hybrid electro-biological systems are reshaping CO₂ capture. Explore the 2026 biocatalytic carbon capture technology landscape.
Article | Report Explore the NK cell therapy pipeline across hematologic and solid tumors — CAR-NK, iPSC-derived, CIML, and NK engager strategies shaping immuno-oncology in 2025.
Article | Report How directed self-assembly (DSA) complements EUV lithography for sub-30 nm contact hole patterning at 3–5 nm nodes. Key materials, process strategies, and IP landscape.
Article | Report How CAR-NK, allogeneic, and iPSC-derived NK cell therapies are reshaping immuno-oncology — covering AML, solid tumors, and the evolving target landscape.